It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
IDH1-mutated gliomas are slow-growing brain tumours which progress into high-grade gliomas. The early molecular events causing this progression are ill-defined. Previous studies revealed that 20% of these tumours already have transformation foci. These foci offer opportunities to better understand malignant progression. We used immunohistochemistry and high throughput RNA profiling to characterize foci cells. These have higher pSTAT3 staining revealing activation of JAK/STAT signaling. They downregulate RNAs involved in Wnt signaling (DAAM2, SFRP2), EGFR signaling (MLC1), cytoskeleton and cell-cell communication (EZR, GJA1). In addition, foci cells show reduced levels of RNA coding for Ethanolamine-Phosphate Phospho-Lyase (ETNPPL/AGXT2L1), a lipid metabolism enzyme. ETNPPL is involved in the catabolism of phosphoethanolamine implicated in membrane synthesis. We detected ETNPPL protein in glioma cells as well as in astrocytes in the human brain. Its nuclear localization suggests additional roles for this enzyme. ETNPPL expression is inversely correlated to glioma grade and we found no ETNPPL protein in glioblastomas. Overexpression of ETNPPL reduces the growth of glioma stem cells indicating that this enzyme opposes gliomagenesis. Collectively, these results suggest that a combined alteration in membrane lipid metabolism and STAT3 pathway promotes IDH1-mutated glioma malignant progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123); Keio University School of Medicine, Physiology Department. 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959)
2 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123)
3 Institute for Regenerative Medicine & Biotherapy, Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.414352.5)
4 Institute of Human Genetics, Centre National de la Recherche Scientifique (CNRS). UMR9002, 141 rue de la Cardonille, Montpellier, France (GRID:grid.462268.c) (ISNI:0000 0000 9886 5504)
5 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123); Neurosurgery Department. Hôpital Gui de Chauliac, 80 Avenue Augustin Fliche, Montpellier, France (GRID:grid.414130.3) (ISNI:0000 0001 2151 3479)
6 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123); Laboratory of Solid Tumors Biology. Hôpital Lapeyronie, 371 Avenue du Doyen Giraud, Montpellier, France (GRID:grid.464046.4)
7 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123); Department of Pathology and Oncobiology. Hôpital Gui de Chauliac, 80 Avenue Augustin Fliche, Montpellier, France (GRID:grid.464046.4)
8 Institute for Neurosciences of Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM). U1051 - Hôpital Saint-Éloi, 80 Avenue Augustin Fliche - 34091 Montpellier cedex 5, Montpellier, France (GRID:grid.464046.4) (ISNI:0000 0004 0450 3123); University of Montpellier, Place Eugène Bataillon, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)